<DOC>
	<DOC>NCT01981837</DOC>
	<brief_summary>The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.</brief_summary>
	<brief_title>Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>TTR cardiac amyloidosis; Women of childbearing potential (WOCBP) must have a negative pregnancy test, cannot be breast feeding, and must be willing to use 2 highly effective methods of contraception; Male subjects agree to use appropriate contraception; Adequate blood counts, liver, renal and heart function; Adequate Karnofsky performance status; Adequate New York Heart Association (NYHA) Classification Score; Clinically stable on heart medications; Adequate 6minute walk test; Willing to give written informed consent and are willing to comply with the study requirements. Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection; Subjects with a history of multiple drug allergies or intolerance to SC injection; Received an investigational agent other than tafamidis, diflunisal, doxycycline or tauroursodeoxycholic acid, or an investigational device within 30 days prior to first dose of study; Uncontrolled hypertension, ischemic heart disease or cardiac arrhythmia; Untreated hypo or hyperthyroidism; Prior major organ transplant; Considered unfit for the study by the Principal Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>